Relief Therapeutics Holding AG (RLFTF)
USD 2.77
(3.19%)
USD 2.77
(3.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 114.94 Million CHF | -69.05% |
| 2022 | 29.22 Million CHF | 55.33% |
| 2021 | 18.81 Million CHF | 175.78% |
| 2020 | 6.82 Million CHF | 818.03% |
| 2019 | 743 Thousand CHF | -26.58% |
| 2018 | 1.01 Million CHF | -40.33% |
| 2017 | 1.69 Million CHF | -2.36% |
| 2016 | 1.73 Million CHF | -12.83% |
| 2015 | 1.99 Million CHF | -90.27% |
| 2014 | 20.47 Million CHF | 8.96% |
| 2013 | 18.79 Million CHF | 318.19% |
| 2012 | 4.49 Million CHF | -92.4% |
| 2011 | 59.16 Million CHF | 201.34% |
| 2010 | 19.63 Million CHF | -24.04% |
| 2009 | 25.84 Million CHF | 9.0% |
| 2008 | 23.71 Million CHF | 43.19% |
| 2007 | 16.56 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.03 Million CHF | 0.0% |
| 2024 Q1 | 4.03 Million CHF | 29.41% |
| 2023 Q1 | 33.14 Million CHF | 277.51% |
| 2023 FY | 9.04 Million CHF | -69.05% |
| 2023 Q2 | 5.92 Million CHF | -82.12% |
| 2023 Q4 | 3.11 Million CHF | -87.42% |
| 2023 Q3 | 24.79 Million CHF | 318.26% |
| 2022 Q2 | 15.74 Million CHF | 2.92% |
| 2022 FY | 29.22 Million CHF | 55.33% |
| 2022 Q3 | 14.22 Million CHF | -9.63% |
| 2022 Q4 | 8.77 Million CHF | -38.28% |
| 2022 Q1 | 15.29 Million CHF | 4.56% |
| 2021 FY | 18.81 Million CHF | 175.78% |
| 2021 Q3 | 11.63 Million CHF | -22.16% |
| 2021 Q4 | 14.62 Million CHF | 25.71% |
| 2021 Q2 | 14.95 Million CHF | 103.83% |
| 2021 Q1 | 7.33 Million CHF | -53.56% |
| 2020 Q2 | 3.5 Million CHF | -29.01% |
| 2020 Q1 | 4.93 Million CHF | 838.69% |
| 2020 Q3 | 8.02 Million CHF | 128.86% |
| 2020 FY | 6.82 Million CHF | 818.03% |
| 2020 Q4 | 15.79 Million CHF | 96.88% |
| 2019 Q2 | 420 Thousand CHF | 57.6% |
| 2019 Q3 | 5.74 Million CHF | 1268.45% |
| 2019 Q1 | 266.5 Thousand CHF | 45.63% |
| 2019 Q4 | 526 Thousand CHF | -90.85% |
| 2019 FY | 743 Thousand CHF | -26.58% |
| 2018 Q4 | 183 Thousand CHF | 0.0% |
| 2018 FY | 1.01 Million CHF | -40.33% |
| 2018 Q3 | 183 Thousand CHF | -13.27% |
| 2018 Q2 | 211 Thousand CHF | 0.0% |
| 2018 Q1 | 211 Thousand CHF | -39.02% |
| 2017 Q3 | 346 Thousand CHF | -34.1% |
| 2017 Q4 | 346 Thousand CHF | 0.0% |
| 2017 Q2 | 525 Thousand CHF | 0.0% |
| 2017 FY | 1.69 Million CHF | -2.36% |
| 2017 Q1 | 525 Thousand CHF | -93.58% |
| 2016 FY | 1.73 Million CHF | -12.83% |
| 2016 Q1 | 135.5 Thousand CHF | 0.0% |
| 2016 Q3 | 8.17 Million CHF | 5931.0% |
| 2016 Q4 | 8.17 Million CHF | 0.0% |
| 2016 Q2 | 135.5 Thousand CHF | 0.0% |
| 2015 FY | 1.99 Million CHF | -90.27% |
| 2014 FY | 20.47 Million CHF | 8.96% |
| 2013 FY | 18.79 Million CHF | 318.19% |
| 2012 FY | 4.49 Million CHF | -92.4% |
| 2011 FY | 59.16 Million CHF | 201.34% |
| 2010 FY | 19.63 Million CHF | -24.04% |
| 2009 FY | 25.84 Million CHF | 9.0% |
| 2008 FY | 23.71 Million CHF | 43.19% |
| 2007 FY | 16.56 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 3.65 Million USD | -3048.459% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -8467.808% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -4274.502% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -288.932% |
| GB Sciences, Inc. | 1.42 Million USD | -7991.536% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -3275.674% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -52127.392% |
| Skye Bioscience, Inc. | 13.54 Million USD | -748.426% |
| Zenith Capital Corp. | 8.94 Million USD | -1185.262% |
| Agentix Corp. | 1.37 Million USD | -8279.114% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -2179.651% |
| Biomind Labs Inc. | 994.18 Thousand USD | -11461.364% |
| ContraFect Corporation | 56.88 Million USD | -102.044% |
| CSL Limited | 3.44 Billion USD | 96.667% |
| CytoDyn Inc. | 18.05 Million USD | -536.51% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -6065.139% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -29404.885% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -100.106% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -27564.695% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -7553.045% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -12346.102% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -208.519% |
| SQZ Biotechnologies Company | 85.61 Million USD | -34.247% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -5510.422% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -32.443% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -3841.418% |
| Mesoblast Limited | 5.9 Million USD | -1847.492% |
| Marizyme, Inc. | 19.23 Million USD | -497.412% |
| Genus plc | 147.7 Million USD | 22.179% |
| Pharming Group N.V. | 225.49 Million USD | 49.026% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -1278.355% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -7672.838% |
| IMV Inc. | 37.7 Million USD | -204.809% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -4019.222% |
| MultiCell Technologies, Inc. | 567.42 USD | -20256676.286% |
| ONE Bio Corp. | 6.44 Million USD | -1683.72% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -33.738% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -365.066% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -6431.934% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -1610.937% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 459864.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -617.922% |
| Alpha Cognition Inc. | 9.7 Million USD | -1084.275% |
| Enzolytics Inc. | 2.17 Million USD | -5173.716% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 92.505% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -10909.674% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -4679.383% |
| Genscript Biotech Corporation | 825.34 Million USD | 86.074% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -2237.191% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -43816.539% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -4581.31% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -66917.474% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -5883.687% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -1209.237% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -2507.157% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -2968.023% |
| Helix BioMedix, Inc. | 1.97 Million USD | -5728.551% |
| EV Biologics, Inc. | 531.96 Thousand USD | -21506.994% |
| Q BioMed Inc. | 3.43 Million USD | -3244.587% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -957.707% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -15.716% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -400.292% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -6163.49% |
| HST Global, Inc. | 140.9 Thousand USD | -81472.243% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -8507.034% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -10117.795% |
| Halberd Corporation | 74.84 Thousand USD | -153478.205% |
| Resverlogix Corp. | 12.71 Million USD | -804.193% |
| Cell Source, Inc. | 4.32 Million USD | -2557.383% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -7177.718% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -1472.324% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -659684.169% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -4559.592% |
| Kadimastem Ltd | 2.41 Million USD | -4669.114% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -2611.887% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -63233.609% |
| LadRx Corporation | 3.81 Million USD | -2915.407% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -12346.102% |
| Affymax, Inc. | 39.38 Million USD | -191.832% |
| Itoco Inc. | 919.14 Thousand USD | -12405.236% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -10171.761% |
| Mobile Lads Corp. | 554.54 Thousand USD | -20627.045% |
| International Stem Cell Corporation | 5.27 Million USD | -2080.63% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -2908.811% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -456576.864% |
| Qrons Inc. | 643.67 Thousand USD | -17756.938% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -7995.622% |
| SYBLEU INC | 160.87 Thousand USD | -71346.953% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -5054.585% |
| Rebus Holdings, Inc. | 664 Thousand USD | -17210.392% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -6228.235% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -218244.668% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -564914.993% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -216.939% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -7003.894% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -15520.486% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -3594.664% |
| Neutra Corp. | 243.82 Thousand USD | -47041.551% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -558.424% |
| PureTech Health plc | 144.59 Million USD | 20.509% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -460.965% |
| IXICO plc | 4.7 Million USD | -2341.916% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -1206.593% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 2.384% |
| CSL Limited | 3.89 Billion USD | 97.047% |
| Cellectis S.A. | 97.32 Million USD | -18.106% |